Table 3 Multivariate analyses evaluating risk factors for CAPA development (panel A) and mortality in the overall population (panel B) and in the CAPA cohort (panel C)

Panel A. Risk factors for CAPA

OR (CI95%)

p-value

Age > 65 years

1.74 (0.75–4.37)

0.21

Hematological malignancy

5.93 (2.26–15.78)

0.0003

Lymphocytopenia^a

2.29 (1.12–4.86)

0.02

Severe or critical COVID-19^b

1.91 (0.81–5.19)

0.16

COPD

2.47 (1.19–5.08)

0.014

Immunodeficiency

2.19 (0.79–5.84)

0.123

Chronic steroid therapy

2.38 (0.98–5.60)

0.05

Anti-IL6 therapy

2.70 (0.48–13.17)

0.23

Panel B. Risk factors for mortality in overall population

OR (CI95%)

p-value

Severe or critical COVID-19^b

3.59 (1.67–8.27)

0.0014

CAPA

2.92 (1.47–5.89)

0.0024

Male sex

0.94 (0.52–1.69)

0.8284

Lymphocytopenia^a

3.23 (1.79–5.97)

0.0001

APACHE II > 9

5.55 (2.97–10.70)

 < 0.0001

CCI > 5

1.59 (0.87–2.91)

0.1292

Panel C. Risk factors for mortality in CAPA cohort

OR (CI95%)

p-value

APACHE II > 9

2.28 (0.60–8.89)

0.224

Age > 65 years

5.09 (1.20–26.92)

0.035